



IMACC
International Multidisciplinary Anal Cancer Consortium

THE 2nd INTERNATIONAL MULTIDISCIPLINARY ANAL CANCER CONFERENCE

9-10 November, 2023

Centro Congressi Europa

Sala Italia Largo Francesco Vito 1

**Catholic University of Sacred Heart -
Policlinico Agostino Gemelli, Rome, Italy**

The 2nd International Multidisciplinary Anal Cancer Conference

9-10 November, 2023 at Catholic University of Sacred Heart - Policlinico Agostino Gemelli, Rome, Italy

Program

Thursday, 9 November 2023

08:30-09:00 Arrival and registration

09:00-09:05 Welcome

Karen-Lise Garm Spindler, Aarhus, Denmark and Maria Antonietta Gambacorta, Rome, Italy

09:05-09:25 Keynote lecture; Humanistic Guided Oncology

Vincenzo Valentini, Rome, Italy

09:25-09:40 Inequalities in anal cancer treatment – how can we contribute?

Eva Segelov, Bern, Switzerland

09:40-10:00 Panel discussion with patient representatives

Moderated by Pierfrancesco Franco, Novara, Italy and Eva Segelov, Bern, Switzerland

10:00-13:00 Session 1: Clinical Trials status, update, and perspectives for collaboration

Chairs: Marianne Guren, Oslo, Norway and David Sebag-Montefiore, Leeds, UK

10:00-10:15 Clinical trials for anal cancer - what have we learnt and what can we do better?

David Sebag-Montefiore, Leeds, UK

10:15-10:30 Evaluating immunotherapy in the curative treatment of anal cancer

Rob Glynne-Jones, London, UK

10:30-11:00 Coffee

11:00-11:15 Defining new standards of care for advanced disease

Sheela Rao, Sutton, UK

11:15-11:30 Future novel agents on the horizon for anal cancer

Dirk Arnold, Hamburg, Germany

11:30-12:15 **Oxford debate: this house believes that neo-adjuvant chemotherapy is a useful treatment strategy for patients with non-metastatic anal cancer**
Chair: David Sebag-Montefiore, Leeds, UK

*Pro - Veronique Vendrel, Bordeaux, France
Con - Rob Glynne-Jones, London, UK*

12:15-13:00 **Proffered papers**

Chairs: Sheela Rao, Sutton, UK and Dirk Arnold, Hamburg, Germany

5 min. presentation – 2 min. discussion

1. Equity challenges in research: Unveiling disparities within Anal Cancer Trials
Daniëlle Verschoor, Bern, Switzerland
2. Standard vs dose reduced chemoradiotherapy in anal cancer: Updated Phase II results of the PLATO-ACT4 RCT ISRCTN88455282
Alexandra Gilbert, Leeds, United Kingdom
3. Role of concomitant chemotherapy in managment of early stage squamous cell carcinoma of the anal canal: ancillary study of the national FFCD-ANABASE cohort.
Claire Lemanski, Montpellier, France
4. Heterogeneity in trial design for radiotherapy-immunotherapy combination studies in squamous cell anal cancer - are we making the same mistakes again?
Robert Samuel, Leeds, United Kingdom
5. GOLET: A phase 1/2 multiple indication study in advanced gastrointestinal cancers treated with pelareorep and atezolizumab – preliminary safety and efficacy results in second-line or later unresectable anal carcinoma
Dirk Arnold, Hamburg, Germany
6. Real-life status on efficacy and outcome after treatment with pembrolizumab in patients with advanced anal cancer in Denmark
Christian Andreas Hvid, AUH, Danmark

13:00-14:00 **Lunch**

14:00-18:00 **Session 2: Biology, Basic and translational science**

Chairs: Duncan Gilbert, London, UK and Karen-Lise Garm Spindler, Aarhus, Denmark

14:00-14:15 **IRCI anal cancer translational science group work**
Duncan Gilbert, London, UK

14:15-14:30 **Hypoxia in SCC Anal cancer, results and perspectives**
Karen Wind, Aarhus, Denmark

14:30-14:45 **PDX generations, and potential use for collaboration**
Morten Busk, Aarhus, Denmark

14:45-15:00 **Microbiome**
Antonio Gasbarrini, Rome, Italy

15:00-15:15 Imaging biomarkers in anal cancer
TBC

15:15-16:30 What is the biological difference between HPV positive and negative disease?
Andrew McDonald, Leeds, UK

15:30-15:45 pHPV studies in SCC – update from pan-scam
Karen-Lise Garm Spindler, Aarhus, Denmark

15:45-16:15 Coffee

16.15-17.15 Proffered papers

Chairs: Per Nilsson, Stockholm, Sweden and Anders Johnsson, Lund, Sweden

5 min. presentation – 2 min. discussion

1. Expression of cancer stem cell markers as potential biomarker in squamous cell carcinoma of the anus
Karen Wind, Aarhus, Denmark
2. Circulating markers of disease in locally advanced anal cancer patients treated within the PLATO trial.
Duncan Gilbert, Brighton, UK
3. Prognostic value of 18F-FDG PET/CT assessment in anal carcinoma in patients from FFCD-ANABASE cohort
Virginie Combet-Curt, Bordeaux, France
4. Efficacy and toxicity of (chemo)radiotherapy in HIV-positive patients with squamous cell anal cancer, a subgroup analysis of the national multicentric cohort ANABASE
Florence Huguet, Paris, France
5. International validation of the EORTC QLQ-ANL27, an anal cancer-specific health-related quality of life questionnaire
Marianne G. Guren, Oslo, Norway
6. SExual QUality Of life In Anal cancer (SEQUOIA): : A prospective longitudinal study
Claire Lemanski, Montpellier, France
7. Late gynecologic toxicity after radiotherapy for anal cancer.
Elizabeth Møller Hedegaard, Aarhus, Denmark
8. Bowel delineation methods and dosimetric predictors of acute and late diarrhea in radiotherapy for anal cancer
Katrine Smedegaard Storm, Copenhagen, Denmark

17:15-18:00 Discussion topics

Moderated by Duncan Gilbert, London, UK and Karen-Lise Garm Spindler, Aarhus, Denmark

18:00-19:00 Poster session

Chairs: Anders Johnson, Lund, Sweden, Marianne Guren, Oslo, Norway, and Per Nilsson, Stockholm, Sweden

19:30- Conference dinner

Endorsed by
ESTRO



Associazione Italiana
Radioterapia e Oncologia clinica



Friday, 10 November 2023

09:00-10:15 Session 3: Improved radiotherapy
Chairs: Pierfrancesco Franco, Novara, Italy and Maria Antonietta Gambacorta, Rome, Italy

09:00-09:15 Where are the limitations with current IMRT based therapy?
Pierfrancesco Franco, Novara, Italy

09:15-09:30 Optimal imaging assessment and new diagnostic tools
TBC

09:30-09:45 Risk adapted target definition
Martin Nilsson, Lund, Sweden

09:45-10:00 AtomCat for all? Update for utility?
Ane Appelt, Leeds, UK

10:00-10:15 Potential of Ethos therapy
Eva Serup-Hansen, Herlev, Denmark

10:15-10:30 Potential of the MR-linac in anal cancer
Giuditta Chiloiro, Rome, Italy

10:30-11:00 Coffee

11:00-12:00 Session 3: Improved radiotherapy (continued)

11:00-11:15 Role of brachytherapy in anal cancer
Bruno Fionda, Rome, Italy

11:15-11:30 Proton therapy in anal cancer
Camilla Kronborg, Aarhus, Denmark

11:30-11:45 Management of radiation proctitis
Carlo Ratto, Rome, Italy

11:45-12:45 Lunch

12:45-13:30 Proffered papers

Chairs: Stefania Manfrida, Rome, Italy and Veronique Vendrel, Bordeaux, France

5 min. presentation – 2 min. discussion

1. De-escalation of elective lymph node volume in early anal cancer treated with chemoradiotherapy – a Swedish cohort study
Sofia Heyman, Gothenburg, Sweden
2. Bonesparing radiotherapy for anal cancer. Plan comparison in the DACG II trial
Camilla Kronborg, Aarhus, Denmark
3. HIT-ART: Highly Tailored Anal cancer MRI guided interventional RadioTherapy (brachytherapy) study: results of 10-year experience
Bruno Fionda, Rome, Italy
4. Electron beam radiotherapy for the management of perianal squamous cell carcinoma
Lars Fokdal, Vejle, Denmark
5. Optimal posttreatment time for magnetic resonance imaging (MRI) response evaluation in squamous cell carcinoma of the anus (SCCA)
Bettina Andrea Hanekamp, Oslo, Norway
6. Impact of time from diagnosis to start of radiotherapy in anal cancer
Jakob Hallström, Lund, Sweden

13:30-15:00 IMACC Discussion

Facilitation of international collaboration, focus and research on anal cancer

Moderated by Dirk Arnold, Hamburg, Germany and David Sebag-Montefiore, Leeds, UK

This program may be subject to minor changes.



With the unconditional contribution of



A Siemens Healthineers Company